国产在线播放91,国内外精品激情刺激在线,日韩性久久

Avidity's FSHD Drug Gains FDA Support Avidity FDA Avidity Biosciences' siRNA therapy delpacibart braxlosiran shows promise in treating FSHD, gaining FDA support for accelerated approval and advancing to Phase III trials.
Metsera's MET-233i Shows 8.4% Weight Loss in Phase 1 Metsera Weight loss drugs Weight loss Weight loss drugs Metsera reports positive Phase 1 results for MET-233i, its once-monthly amylin analog, showing up to 8.4% weight loss and strong tolerability. Combination trials with GLP-1 therapy underway.
Zai Lab Breakthrough at ASCO: DLL3 ADC and TTFields Pancreatic Cancer Advances ASCO Biotech Zai Lab Discover how biotech leader Zai Lab is making waves at ASCO with groundbreaking DLL3 ADC clinical data and innovative TTFields therapy expanding into pancreatic cancer, driving strong growth and strategic transformation.
ASCO 2025: Opening a New Era of "Cancer Eradication" ASCO Cancer AstraZeneca Amgen Daiichi Sankyo Discover the latest breakthroughs from ASCO 2025, including innovative cancer treatments, immunotherapy advances, bispecific antibodies, and promising breast cancer therapies shaping the future of oncology.
Cullinan Licenses $700M+ Autoimmune Drug from China Biotech Genrix Autoimmune Drug Autoimmune Cullinan Therapeutics Genrix Bio Cullinan Therapeutics signs a $700M+ licensing deal with China’s Genrix Bio for global rights to velinotamig, a bispecific T cell engager targeting autoimmune diseases, expanding its pipeline and global R&D strategy.
ASCO 2025: AstraZeneca's Breakthrough Innovations in Cancer Treatment Leading Global Oncology Advances ASCO Market Trend AstraZeneca Discover AstraZeneca’s groundbreaking cancer research at ASCO 2025, featuring innovative therapies in breast, lung, and digestive cancers. Leading global oncology with advanced treatments and strategic local-global integration.
MoonLake Immunotherapeutics Rejects Merck's $3B Buyout Amid Promising IL-17 Pipeline Merck MoonLake Immunotherapeutics MoonLake Immunotherapeutics has rejected Merck’s $3B acquisition offer, choosing to advance its promising IL-17A/F antibody Sonelokimab, now in Phase III trials for autoimmune diseases like HS and PsA.
Eli Lilly and Camurus Sign $870M Deal for Long-Acting Incretin Therapies Using FluidCrystal? Technology Eli Lilly Camurus Eli Lilly partners with Camurus in an $870M deal to develop long-acting incretin therapies using FluidCrystal? technology, aiming to improve treatment adherence for obesity, diabetes, and chronic diseases.
ASCO 2025: BMS Defends Opdualag's Future After Adjuvant Melanoma Setback BMS ASCO Market Trend Bristol Myers Squibb’s Opdualag failed to improve outcomes in adjuvant melanoma, raising questions about LAG-3 antibodies. Despite this, BMS remains confident in ongoing NSCLC trials targeting PD-1 positive patients.
Bayer’s Nubeqa Gains FDA Expansion for Broader Prostate Cancer Use Bayer FDA Bayer secures FDA approval to expand Nubeqa's use for all metastatic castration-sensitive prostate cancer patients, including those unable to tolerate chemotherapy, strengthening its position in the prostate cancer treatment market.